ReviewAntiviral research2016
Norovirus drug candidates that inhibit viral capsid attachment to human histo-blood group antigens.
Review in Antiviral research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Increase of GII.17 Norovirus Infections During the 2024-2025 Season in Multiple Cities, China.Journal of medical virology · 2026Article
- A pan-respiratory virus attachment inhibitor with high potency in human airway models and in vivo.Science advances · 2025Article
- Current and Future Antiviral Strategies to Tackle Gastrointestinal Viral Infections.Microorganisms · 2021Review
- Viruses Like Sugars: How to Assess Glycan Involvement in Viral Attachment.Microorganisms · 2021Review
- Fucoidan But Not 2'-Fucosyllactose Inhibits Human Norovirus Replication in Zebrafish Larvae.Viruses · 2021Article
- Effects of Epigallocatechin-3-Gallate-Palmitate (EC16) onMicrobiology & infectious diseases (Wilmington, Del.) · 2021Article
- The Effect of GD1a Ganglioside-Expressing Bacterial Strains on Murine Norovirus Infectivity.Molecules (Basel, Switzerland) · 2020Article
- Structure-based exploration and exploitation of the SEuropean journal of medicinal chemistry · 2017Article
- Norovirus Binding to Ligands Beyond Histo-Blood Group Antigens.Frontiers in microbiology · 2017Review
- Antiviral strategies against human norovirus: Molecular targets, therapeutics, and vaccine development.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Human noroviruses are the leading causative agents of epidemic and sporadic viral gastroenteritis and childhood diarrhoea worldwide. Human histo-blood group antigens (HBGA) serve as receptors for norovirus capsid protein attachment and play a critical role in infection. This makes HBGA-norovirus binding a promising target for drug development. Recently solved crystal structures of norovirus bound to HBGA have provided a structural basis for identification of potential anti-norovirus drugs and subsequently performed in silico and in vitro drug screens have identified compounds that block norovirus binding and may thereby serve as structural templates for design of therapeutic norovirus inhibitors. This review explores norovirus therapeutic options based on the strategy of blocking norovirus-HBGA binding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.